Lupus Nephritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Lupus Pipeline Comprising a Broad Spectrum of Molecular Targets

Lupus Nephritis Pipeline encompasses promising therapies with an aim to meet the unmet need in the Lupus Nephritis treatment space.

New Delhi, INDIA


Las Vegas, USA, July 19, 2021 (GLOBE NEWSWIRE) -- Lupus Nephritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Lupus Pipeline Comprising a Broad Spectrum of Molecular Targets

Lupus Nephritis Pipeline encompasses promising therapies with an aim to meet the unmet need in the Lupus Nephritis treatment space.

DelveInsight’s Lupus Nephritis Pipeline Insights report lays down a holistic coverage of the available therapies, Lupus Nephritis pipeline therapies in different phases of clinical development, key companies active in the Lupus Nephritis pipeline domain, drivers and barriers in the successful launch of the therapies and future trends. 

Some of the notable pointers extracted from the Lupus Nephritis Pipeline report:

  • DelveInsight’s analysis depicts a robust Lupus Nephritis Pipeline with 24+ active players in the domain working on 24+ pipeline therapies
  • Key Lupus Nephritis pipeline therapies such as AT-1501, Zanubrutinib, Secukinumab, NTR-441, Guselkumab, Obinutuzumab, BMS-986165, LABP-104, SHR-1314, Itolizumab, Ravulizumab, BI-655064, OMS721, Sirolimus, and others are under investigation in different phases of clinical trials for the treatment of Lupus Nephritis. 
  • Roche, Omeros Corporation, Novartis, BeiGene, Janssen Biotech, Bristol-Myers Squibb, Eledon Pharmaceuticals, Neutrolis Therapeutics, Landos Biopharma, Equillium, Suzhou Suncadia Biopharmaceuticals, Alexion Pharmaceuticals, Boehringer Ingelheim, North China Pharmaceutical Group among several others are some of the key prominent pharma players working in the domain. 
  • In August 2020, Roche initiated a Phase III randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Obinutuzumab in patients with ISN/RPS 2003 Class III Or IV lupus nephritis. Results of the Phase II NOBILITY trial showed that obinutuzumab (Gazyva, Genentech) was well-tolerated with “no unexpected safety findings” by week 104.
  • In June 2021, North China Pharmaceutical Group Corporation in collaboration with Peking Union Medical College Hospital are planning to initiate a Phase III, single-center, one-arm, open-label pilot study to investigate the efficacy of sirolimus for mild proteinuric flares in patients with Class III/IV±V lupus nephritis.

Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ Lupus Nephritis Emerging Therapies and Forecast 

The Lupus Nephritis Pipeline report covers the ongoing clinical trials, deals, mergers & acquisitions taking place in the domain, recent approvals and failures in space, and growth prospects across the Lupus Nephritis domain.

Lupus Nephritis Overview

Lupus Nephritis (LN), is one of the most severe organ manifestations of Systemic Lupus Erythematosus (SLE), which is an autoimmune disorder. The condition leads to the loss of immune tolerance of endogenous nuclear material resulting in systemic autoimmunity that causes damage to various tissues and organs.

Discover more about the disease, treatments, and pipeline therapies @ Lupus Nephritis Pipeline Assessment 

Lupus Nephritis Pipeline Drugs 

DrugCompanyPhaseMoARoA
AT-1501Eledon PharmaceuticalsPhase ICD40 ligand inhibitorsInjectable
ZanubrutinibBeiGenePhase IIAgammaglobulinaemia tyrosine kinase inhibitorsOral
SecukinumabNovartisPhase IIIIL17A protein inhibitorsSubcutaneous
NTR-441Neutrolis TherapeuticsPreclinicalExtracellular trap inhibitorsNA
GuselkumabJanssen Research & DevelopmentPhase IIInterleukin-23 subunit p19 inhibitorsIntravenous
ObinutuzumabRochePhase IIIAntibody-dependent cell cytotoxicityCD20
LABP-104Landos BiopharmaPreclinicalLANCL2 agonistOral
ItolizumabEquilliumPhase ICD6 antigen inhibitorsSubcutaneous
BI-655064Boehringer IngelheimPhase IICD40 antigen inhibitorsSubcutaneous
NipocalimabJanssen Research & DevelopmentPhase IIFc receptor antagonistsIntravenous

Request for Sample to know more @ Lupus Nephritis Pipeline Analysis, Key Companies, and Futuristic Trends 

Lupus Nephritis Therapeutics Assessment 

The Lupus Nephritis Pipeline report proffers an integral view of the Lupus Nephritis emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

  • Mono
  • Combination

By Stage

  • Discovery 
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III

By Molecule Type 

  • Small molecules
  • Monoclonal antibodies

By Route of Administration

  • Subcutaneous
  • Intravenous
  • Oral
  • Injectable

By Mechanism of Action

  • CD6 antigen inhibitors
  • Agammaglobulinemia tyrosine kinase inhibitors
  • CD40 ligand inhibitors
  • Antibody-dependent cell cytotoxicity
  • Interleukin-23 subunit p19 inhibitors
  • LANCL2 agonist
  • Interferon-alpha inhibitors
  • IL17A protein inhibitors
  • Extracellular trap inhibitors

By Targets

  • IL17A protein
  • CD20
  • Agammaglobulinemia tyrosine kinase
  • Complement C5
  • MASP2 protein
  • CD40 antigen
  • Interleukin-23 subunit p19
  • TYK2 kinase
  • Complement C3

For rich insights into merging therapies and assessment, visit Lupus Nephritis Pipeline Emerging Novel Therapies 

Scope of the Lupus Nephritis Drug Pipeline Report

Coverage: Global
Key Players: Roche, Omeros Corporation, Novartis, BeiGene, Janssen Biotech, Bristol-Myers Squibb, Eledon Pharmaceuticals, Neutrolis Therapeutics, Landos Biopharma, Equillium, Suzhou Suncadia Biopharmaceuticals, Alexion Pharmaceuticals, Boehringer Ingelheim, North China Pharmaceutical Group, among others.
Key Lupus Nephritis Pipeline Therapies: AT-1501, Zanubrutinib, Secukinumab, NTR-441, Guselkumab, Obinutuzumab, BMS-986165, LABP-104, SHR-1314, Itolizumab, Ravulizumab, BI-655064, OMS721, Sirolimus, and several others. 

Discover more about the scope of the report @ Lupus Nephritis Emerging Therapies, Treatments, and Ongoing Clinical Trials 

Table of Contents 

1Report Introduction
2Executive Summary
3Lupus Nephritis Disease Overview
4Lupus Nephritis Pipeline Therapeutics Comparative Analysis
5Lupus Nephritis Therapeutic Assessment
6In-depth Commercial Assessment
7Lupus Nephritis – DelveInsight’s Analytical Perspective
8In-depth Commercial Lupus Nephritis Assessment
9Lupus Nephritis Collaboration Deals 
10Late Stage Lupus Nephritis Products (Phase III)
11Mid-Stage Lupus Nephritis Products (Phase II)
12Early Stage Lupus Nephritis Products (Phase I)
13Pre-clinical and Discovery Stage Lupus Nephritis Products
14Inactive Lupus Nephritis Pipeline Products 
15Key Lupus Nephritis Products
16Unmet Needs
17Lupus Nephritis Market Drivers and Barriers
18Future Perspectives and Conclusion
19Analyst Views
20Key Lupus Nephritis Companies
21Appendix

Learn more about the report offerings @ Lupus Nephritis Pipeline Therapies and Emerging Trends 

Audit the market before venturing with DelveInsight’s Due Diligence Services  

Related Reports

Lupus Nephritis Market
DelveInsight's "Lupus Nephritis (Lupus Nephritis) Market Insights, Epidemiology and Market Forecast-2028" report.

Cutaneous Lupus Erythematosus Market
DelveInsight's "Cutaneous Lupus Erythematosus - Market Insights, Epidemiology, and Market Forecast-2030" report.

Systemic Lupus Erythematosus Market
DelveInsight's "Systemic Lupus Erythematosus - Market Insights, Epidemiology, and Market Forecast-2030" report.

Alopecia Market
DelveInsight's "Alopecia Market Insights, Epidemiology, and Market Forecast-2030" report.

Androgenetic Alopecia Market
DelveInsight's "Androgenetic Alopecia Market Insights, Epidemiology, and Market Forecast-2030" report.

Browse through our posts 

JAK Inhibitors Market
Janus kinase inhibitors (JAKs) have experienced dramatic ups and downs in their path to get market access in recent years, varying from blockbuster medications to black box warnings. In terms of safety, this class has experienced bewildering twists and turns. Despite the challenges, pharmaceutical’s belief in JAKs’ ability to create a paradigm shift in patient care means R&D activity and interest continues unabated.

FemTech Market
With 100+ Startups in the domain, Women Healthcare Market is Witnessing Exponential Traction 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 

 

Contact Data